Fagron Nederland Revenue and Competitors
Employee Data
- Fagron Nederland has 82 Employees.
- Fagron Nederland grew their employee count by 19% last year.
Fagron Nederland's People
Name | Title | Email/Phone |
---|---|---|
1 | Regulatory Affairs Officer | Reveal Email/Phone |
2 | Area General Manager | Reveal Email/Phone |
3 | Marketing & Communications Manager NL | Reveal Email/Phone |
4 | Pharmaceutical Account Manager | Reveal Email/Phone |
5 | Business Manager Extramuraal & Intramuraal | Reveal Email/Phone |
6 | Commercieel manager| Head sales | Reveal Email/Phone |
7 | Demand planner | Reveal Email/Phone |
8 | Warehouse Supervisor | Reveal Email/Phone |
9 | Specialist eCommerce | Reveal Email/Phone |
10 | Quality control supervisor | Reveal Email/Phone |
Fagron Nederland Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 82 | 19% | N/A | N/A |
#2 | N/A | 62 | 29% | N/A | N/A |
#3 | N/A | 76 | 19% | N/A | N/A |
#4 | N/A | 7 | 0% | N/A | N/A |
#5 | N/A | 6 | 20% | N/A | N/A |
What Is Fagron Nederland?
Als toonaangevende wereldwijde onderneming in farmaceutische bereidingen, heeft Fagron als doel maatwerk medicatie beschikbaar te stellen aan ziekenhuizen, apothekers en patiënten wereldwijd. Fagron, FArmaceutische GRONdstoffen, is in 1990 opgericht in Rotterdam en beursgenoteerd in Euronext Brussel en Amsterdam sinds 5 oktober 2007. Inmiddels is Fagron actief in 34 landen verdeeld over 5 continenten. Ruim 2000 FTE, inclusief meer dan 200 apothekers, werken dagelijks aan innovatieve oplossingen en concepten, die inspelen op de behoeften van apotheker, voorschrijver en patiënt.
keywords:N/AN/A
Total Funding
82
Number of Employees
N/A
Revenue (est)
19%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 83 | 34% | N/A |
#2 | N/A | 88 | 33% | N/A |
#3 | $12.7M | 91 | 8% | N/A |
#4 | $13.3M | 92 | 8% | N/A |
#5 | $13.3M | 92 | 8% | N/A |